Tebentafusp is under clinical development by Immunocore and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II drugs for Uveal Melanoma have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tebentafusp’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tebentafusp overview
Tebentafusp-Tebn (Kimmtrak) is a bispecific gp100 peptide-HLA-directed CD3 T cell engager. It is formulated as the solution, concentrated solution for intravenous route of administration. Kimmtrak is indicated for the treatment of uveal melanoma and advanced cutaneous melanoma.
It was under development for the treatment of unresectable or metastatic uveal melanoma.
Immunocore overview
Immunocore is a biotechnology company. It develops a novel class of TCR bispecific immunotherapies, known as ImmTAX, to treat cancer, infectious diseases, and autoimmune conditions. The company’s lead product, Kimmtrak (tebentafusp), is approved for metastatic uveal melanoma and is being tested in advanced cutaneous melanoma and adjuvant uveal melanoma. Immunocore’s pipeline includes IMC-F106C in Phase 3 for cutaneous melanoma and other candidates like IMC-P115C, IMC-T119C, and IMC-R117C targeting various cancers. The company also advances treatments for HIV and HBV through its ImmTAV platform and develops autoimmune therapies, including IMC-S118AI for type 1 diabetes, offering tissue-specific modulation without broad immunosuppression. Immunocore is headquartered in Abingdon, Oxfordshire, the UK.
For a complete picture of Tebentafusp’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
